Resistance to EGFR-Targeted Therapy: A Family Affair

Gregory Vlacich, Robert J. Coffey

Research output: Contribution to journalShort surveypeer-review

52 Scopus citations


The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.

Original languageEnglish
Pages (from-to)423-425
Number of pages3
JournalCancer Cell
Issue number4
StatePublished - Oct 18 2011


Dive into the research topics of 'Resistance to EGFR-Targeted Therapy: A Family Affair'. Together they form a unique fingerprint.

Cite this